1-4 of 4
P. Rousselot
Close
Sort by
Journal Articles

Dasatinib (SPRYCEL®) 50mg or 70mg BID Versus 100mg or 140mg QD in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Resistant or Intolerant to Imatinib: Results of the CA180-034 Study.

Andreas Hochhaus, D.W. Kim, P. Rousselot, P.E. Dorlhiac-Llacer, J. Milone, S. Francis, E. Bleickardt, H. Kantarjian
Journal: Blood
Blood (2006) 108 (11): 166.
https://doi.org/10.1182/blood.V108.11.166.166
Published: 2006
Journal Articles

Dasatinib (SPRYCEL®) vs Escalated Dose of Imatinib (im) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Resistant to Imatinib: Results of the CA180-017 START-R Randomized Study.

Neil Shah, R. Pasquini, P. Rousselot, S. Jootar, J. Holowiecki, A. Countouriotis, D. Dejardin, T. Hughes, Brian J. Druker
Journal: Blood
Blood (2006) 108 (11): 167.
https://doi.org/10.1182/blood.V108.11.167.167
Published: 2006
Journal Articles

Trisomy 4, a New Chromosomal Abnormality in Waldenstrom’s Macroglobulinemia.

C. Terre, F. N. Guyen-Khac, C. Barin, M.J. Moziconacci, V. Eclache, C. Leonard, H. Farhat, A. Bouyon, P. Rousselot, S. Choquet, V. Leblond, S. Castaigne
Journal: Blood
Blood (2005) 106 (11): 2841.
https://doi.org/10.1182/blood.V106.11.2841.2841
Published: 2005
Journal Articles

A Phase II Study of Dasatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Crisis Who Are Resistant or Intolerant to Imatinib: First Results of the CA180006 ‘START-B’ Study.

M. Talpaz, P. Rousselot, D.W. Kim, F. Guilhot, S. Corm, E. Bleickardt, R. Zink, G. Rosti, S. Coutre, C. Sawyers
Journal: Blood
Blood (2005) 106 (11): 40.
https://doi.org/10.1182/blood.V106.11.40.40
Published: 2005